Previous 10 | Next 10 |
2024-05-16 07:33:17 ET More on AIM ImmunoTech AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech Read ...
Continued execution across Ampligen ® clinical development programs and growing body of positive data in multiple high-value indications Company to host conference call and webcast today, May 16, at 8:30 AM ET OCALA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
2024-05-15 11:47:59 ET Major earnings expected before the bell on Thursday include: Baidu ( BIDU ) Deere & Co. ( DE ) JD.com( JD ) Under Armour ( UAA ) Walmart ( WMT ) Other earnings slated for release before Thursday's open include: ...
2024-05-15 11:26:43 ET More on AIM ImmunoTech AIM ImmunoTech Inc. (AIM) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech Read ...
OCALA, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q1 2024 operational and financial res...
OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen ® (rintatolimod), AIM’s...
OCALA, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has taken an essential step forward in testing the combination of AIM’s Ampligen® (rintatolimod) and AstraZ...
2024-04-19 17:12:59 ET More on AIM ImmunoTech AIM stock dips amid mixed results for post-COVID fatigue therapy Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech ...
OCALA, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced that Charles Lapp, MD, is joining the company to help lead its efforts to develop Ampligen (rintatolimod) as a potential treatment for Myalgic encephalomyelit...
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a ...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...
OCALA, Fla., May 31, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 5,640,958 shares of common stoc...